Search company, investor...

BlossomHill Therapeutics

bhtherapeutics.com

Founded Year

2020

Stage

Series A | Alive

Total Raised

$73M

Last Raised

$71M | 2 yrs ago

About BlossomHill Therapeutics

BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Headquarters Location

6370 Lusk Blvd. Ste. F205

San Diego, California, 92121,

United States

Missing: BlossomHill Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BlossomHill Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BlossomHill Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BlossomHill Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest BlossomHill Therapeutics News

BlossomHill Therapeutics Closes $71M Series A Financing

Mar 4, 2021

BlossomHill Therapeutics Closes $71M Series A Financing SAN DIEGO, March 3, 2021-- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71 million in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads. In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company's Board of Directors. "Peter and I founded BlossomHill Therapeutics to continue our pursuit to help bring new hope to cancer patients through deeper science and innovative drug design,” said Dr. J. Jean Cui, Co-Founder, President and CEO. "We are very delighted to have strong support from this group of stellar investors in this Series A round of financing, and to have Bihua, George, and Carl join our Board of Directors." "We are living in a golden age of bringing precision cancer therapy to patients with actionable mutations. Cormorant is privileged to have the opportunity to partner with Dr Cui again to enable her unique drug design capability to bring powerful innovative medicine to patients in need," remarked Bihua Chen, Cormorant Asset Management. “We are excited to partner with Peter & Jean, who have strong insight in identifying key clinical needs and addressing them with targeted small molecule drugs,” commented Carl Gordon, OrbiMed Advisors. Proceeds from the financing will be used to fund the research and development efforts at BlossomHill Therapeutics and advance lead pipeline projects into clinical development. BlossomHill Therapeutics is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech veteran, Y. Peter Li, Ph.D., M.B.A. Drs. Cui and Li are also the founders of Turning Point Therapeutics, Inc. About BlossomHill Therapeutics, Inc. BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D. and biotech veteran, Y. Peter Li, Ph.D., M.B.A. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds which include Crizotinib, Lorlatinib, Repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131.

BlossomHill Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BlossomHill Therapeutics Rank

BlossomHill Therapeutics Frequently Asked Questions (FAQ)

  • When was BlossomHill Therapeutics founded?

    BlossomHill Therapeutics was founded in 2020.

  • Where is BlossomHill Therapeutics's headquarters?

    BlossomHill Therapeutics's headquarters is located at 6370 Lusk Blvd., San Diego.

  • What is BlossomHill Therapeutics's latest funding round?

    BlossomHill Therapeutics's latest funding round is Series A.

  • How much did BlossomHill Therapeutics raise?

    BlossomHill Therapeutics raised a total of $73M.

  • Who are the investors of BlossomHill Therapeutics?

    Investors of BlossomHill Therapeutics include Cormorant Asset Management, OrbiMed Advisors, Vivo Capital, Amkey Ventures and Hercules BioVentures Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.